Astel­las snaps up mi­to­chon­dria-fo­cused biotech, beefs up drug dis­cov­ery in bud­get deal

Astel­las has shown it can go big when it sees some­thing it wants for the sprawl­ing R&D or­ga­ni­za­tion it’s build­ing, wa­ger­ing $3 bil­lion on gene ther­a­py up­start Au­dentes and $665 mil­lion on Xyphos Bio­sciences’ Park­er-backed CAR-T plat­form. But it can al­so go small. In its lat­est deal, the Japan­ese phar­ma is sub­sum­ing Nan­na Ther­a­peu­tics in­to its Eu­ro­pean unit for less than $15 mil­lion (£12 mil­lion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER